Table 2.

Subject demographic data (skin)

	DLE+/SLE+	DLE+/SLE−	Psoriasis	Normal
N	10	10	5	10
Age at visit, yr (SD)	46 (13)	41 (11)	58 (6)	44 (8)
Gender (M/F)	2/8	2/8	1/4	1/9
Ethnicity, No. (%)
Caucasian	2 (20%)	0 (0%)	5 (100%)	8 (80%)
African American	6 (60%)	8 (80%)	0 (0%)	2 (20%)
Hispanic	2 (20%)	2 (20%)	0 (0%)	0 (0%)
Asian	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Other	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CLASI activity score, mean (SD)	12 (12)	8 (6)	N/A	N/A
CLASI damage score, mean (SD)	14 (14)	12 (5)	N/A	N/A
SLEDAI score, mean (SD)	4 (3)	0 (0)	N/A	N/A
PASI score, mean (SD)	N/A	N/A	7 (5)	N/A
Disease Duration, yr (SD)	10 (9)	7 (8)	5 (7)	N/A
Lupus medications at study visit, No. (%)
Topical/Intralesional Corticosteroids	5 (50%)	7 (70%)	2 (40%)	N/A
Topical Immunomodulators	1 (10%)	0 (0%)	0 (0%)	N/A
Hydroxychloroquine	4 (40%)	5 (50%)	0 (0%)	N/A
Chloroquine	1 (10%)	0 (0%)	0 (0%)	N/A
Prednisone	3 (30%)	0 (0%)	0 (0%)	N/A
Mycophenolate mofetil	1 (10%)	1 (10%)	0 (0%)	N/A
Acitretin	0 (0%)	0 (0%)	1 (20%)	N/A
None	0 (0%)	0 (0%)	3 (60%)	N/A
SLE criteria, No. (%)^a
Malar rash	4 (40%)	0 (0%)	N/A	N/A
Discoid rash	10 (100%)	10 (100%)	N/A	N/A
Photosensitivity	9 (90%)	7 (70%)	N/A	N/A
Oral ulcers	5 (50%)	3 (30%)	N/A	N/A
Arthritis	6 (60%)	0 (0%)	N/A	N/A
Serositis	2 (20%)	0 (0%)	N/A	N/A
Renal disorder	3 (30%)	0 (0%)	N/A	N/A
Hematological disorder	7 (70%)	2 (20%)	N/A	N/A
Anti-nuclear antibody	10 (100%)	3 (30%)	N/A	N/A
Immunological disorder	7 (70%)	0 (0%)	N/A	N/A
Mean # of SLE criteria (SD)	6 (1)	3 (1)	N/A	N/A

None of the DLE patients had neurological disorder.

Abbreviations: CLASI = Cutaneous Lupus Disease Activity and Severity Index; DLE = discoid lupus erythematosus; PASI = Psoriasis Activity and Severity Index; SLE = Systemic Lupus Erythematosus; SLEDAI = Systemic Lupus Erythematosus Disease and Activity Index